Progress in bacterial therapy for cancer and infectious diseases is hampered by the absence of safe and efficient vectors. Sustained delivery and high gene expression levels are critical for the therapeutic efficacy. Here we developed a Salmonella typhimrium strain to maintain and safely deliver a plasmid vector to target tissues. This vector is designed to allow dual transcription of therapeutic factors, such as cytotoxic proteins, short hairpin RNAs or combinations, in the nucleus or cytoplasm of eukaryotic cells, with this expression sustained by an autocatalytic positive-feedback loop. Mechanisms to prime the system and maintain the plasmid in the bacterium are also provided. Synergistic effects of attenuated Salmonella and our inter-kingdom system allow the precise expression of Diphtheria toxin A chain (DTA) gene in tumor microenvironment and eradicate large established tumors in immunocompetent animals. In the experiments reported here, 26% of mice (n=5/19) with aggressive tumors were cured and the other all survived until the end of the experiment. We also demonstrated that ST4 packaged with shRNA-encoding plasmids has sustained knockdown effects in nude mice bearing human MDA-MB-231 xenografts. Three weeks after injection of 5×10 6 ST4/pIKT-shPlk, PLK1 transcript levels in tumors were 62.5 ± 18.6% lower than the vector control group (P=0.015). The presence of PLK1 5′ RACE-PCR cleavage products confirmed a sustained RNAi-mediated mechanism of action. This innovative technology provides an effective and versatile vehicle for efficient inter-kingdom gene delivery that can be applied to cancer therapy and other purposes.
Introduction
The use of bacteria as therapeutic agents has become an increasingly important area of investigation. Their low cost, fast production, diverse natural and modified tropism profiles, high packaging capacity, coupled with their relative tolerance of the immune system and relative ease of control in the case of adverse events, make bacterial-mediated delivery an attractive alternative for gastrointestinal [1] , respiratory [2] , urogenital tracts [3] and solid tumors [4, 5] . Most studies use attenuated bacteria in some way to decrease virulence [6] [7] [8] and augment their natural cytotoxicity with vectors designed to deliver an agent to the target organs [9] [10] [11] [12] [13] [14] [15] . However, to date, clinical trials of bacterial mediated therapy have had modest results [5, 16] . Limiting factors include the bacterial virulence [17] , the effects of host immune response to their presence [18] , the efficiency of intracellular delivery of multiple agents to target cells, instability of the plasmid vector leading to its loss in the bacteria [19] , and inefficient transport of expression plasmids [20] to the nucleus to ensure an optimal dose level of therapeutic agents [21] .
Using enhanced recombineering methods [22] , we previously developed an "obligate"
anaerobic Salmonella strain with enhanced host safety and anti-tumor activity [23, 24] . Here we build on that to develop a new platform that overcomes the above limitations while retaining some of its benefits. S. typhimurium strain SL7207, an aroA deficient strain [25] was used to engineer a series of Salmonella strains (Table S1 ) that have enhanced safety towards the host organism and an increased ability to deliver therapeutic payloads. We demonstrate a live microbe-based inter-kingdom system to deliver therapeutic vectors in a manner that does not compromise host safety and provides greatly improved stability, enhanced intracellular delivery and sustained expression of versatile therapeutic agents (including proteins or RNA molecules), which can target multiple gene networks.
Expression of the payloads is "primed" in mammalian cells through the transfer of both a therapeutic plasmid containing a foreign gene driven by dual promoters and an initial source of T7 RNA polymerase (T7 RNAP) enzyme, and propagated by an auto-feedback system. This therapeutic plasmid has been designed so that it can contain different payloads that are capable of being expressed through both the cytoplasmic and nuclear systems in a mammalian cell and regulated by a feedback system. Maintenance of the plasmid in the bacterium is managed by relocating an essential bacterial gene infA from the bacterial chromosome onto the plasmid. It is the first report to date describing the design and use of a dual expression system incorporated with an amplification loop in gene therapy, which is based on an inter-kingdom interaction of bacteria and higher organisms. In vivo efficacy on tumor tissue and considerably improvement over existing techniques were demonstrated.
Materials and methods

Bacterial strains, animals, cell lines, enzymes and chemicals
Salmonella typhimurium strain SL7207 was kindly provided by Dr. B.A.D Stocker.
Strains and plasmids are described in Table S1 . Six-week-old female nu/nu athymic and BALB/c mice were purchased from the Laboratory Animal Unit of the University of Hong Collection and cultured under conditions specified by the manufacturer. Enzymes were from New England Biolabs and chemicals were from Sigma-Aldrich
Construction of Salmonella mutants
The λ-Red recombination system (plasmid pSim6; a gift from Dr. Donald Court) was used to make genetic manipulations. A PCR-amplified CM-T7 RNAP cassette was electroporated into recombination-competent SL7207 cells and selected on chloramphenicol Luria-Bertani (LB) plates. The correct colony was confirmed by PCR and subsequently self-excised the antibiotic resistance, generating ST1. For the integration of Listeriolysin O （LLO） expression cassette, an integration vector backbone pYB-asd (a pBSK derivate with 1 kb flanking regions of asd sites) was generated. The PsseA-hlyA and loxP-CM-loxP cassettes were ligated to NotI, XhoI and XhoI respectively, to construct plasmid pYB-asd-hlyA. Then the CM-PsseA-hlyA genetic circuit was digested by KpnI and SacII and transformed into ST1 cells induced for the λ-Red recombination to create strain ST2. Thirdly, a similar recombineering strategy was used to replace htrA gene by CM-PpepT-asd-sodA cassette in ST3. Fourthly, a 'precise' deletion of infA locus from ST3 has been performed. Plasmid pET28a-infA containing E.coli MG1655 infA expression cassette has been constructed and co-transformed with pSim6 into ST3. Strain ST5 was constructed similarly, but using GFP instead of LLO. A tetR selection cassette flanking with long homology arms of infA site was purified and transformed. PCR amplification of the new junctions between the drug marker and infA homology arm-flanking DNA was performed to confirm that the wild-type copy of infA was removed. The resulting strain ST4 was confirmed by colony PCR for site-specific integration of the targeting constructs (Table S2 and Fig. S1 ).
In vitro studies
Bacteria were harvested at the late logarithmic phase and then added at Multiplicity of infections (MOIs) ranging from 50 to 200 to cell monolayers. After 4 h, the cells were washed and grown for additional 24-72 h in complete medium containing 10 μg/ml of Gentamycin (Life Technologies).
Cells were arrested at G1 phase by double Thymidine block (at a concentration of 5 mM) or treated with 20 μg/ml Rifampicin, 1 μg/ml α-Amanitin or 1 μg/ml Cycloheximide to inhibit transcription or translation. To evaluate EGFP expression, total proteins were extracted by analysis buffer according to the GFP Quantization Kit (Biovision) and analysed by a Varioskan Flash spectral scanning multimode reader (Thermo Scientific). For quantification, the infected cells were detached and analysed by flow cytometry using a FACScalibur cytometer (Becton-Dickinson) and software WinMDI2.9.
Cell viability was measured using 5-diphenyltetrazolium bromide (MTT) according to the producer's protocol. For apoptosis assay, cells were harvested and stained with Annexin-V/ Propidium iodide (PI) assay kit (BD Biosciences), followed by flow cytometric analysis. 
Tumor xenograft and in vivo studies
Real-time PCR quantification and western blot analysis
Total RNA was extracted by using TRIzol® (Life Technologies). Contaminating DNA was removed with DNase I and cDNA was generated using Superscript III First-strand Synthesis kit (Life Technologies). Anchored oligo (dT) 20 primer was used to hybridize to the poly (A) tail of mRNA transcribed from the nuclear system. Gene specific primers with an adapter were used to prime all the mRNA from both nuclear as well as cytoplasmic system.
After cDNA synthesis, sequence-specific amplification was detected by a fluorescent signal of SYBR Green (ABI) by using Real-time PCR Detector (ABI7500). For western blotting, protein samples were separated on SDS-PAGE gels and then transferred to PVDF membranes (Millipore). Membranes were processed following the ECL western blotting protocol (Millipore).
ELISA assay of Diphtheria toxin A subunit
Briefly, 96-well plates were coated with a mouse anti-Diphtheria toxin A subunit (Maridian) monoclonal antibody in a dilution of 1:500 and blocked by PBS with 5% BSA.
FLAG-tagged DT A chain was expressed by bacteria and purified by anti-FLAG M2 beads (Sigma-Aldrich). Protein concentration was determined by Bradford Reagent Assay. Tumor lysates were diluted in PBS with 2% BSA to concentrations within the liner range of the standard curve. A rabbit anti-FLAG antibody (Cell signalling) conjugated with horseradish peroxidase was used as the secondary antibody in a dilution of 1:8000.
Histology
Mice were intraperitoneally injected with a hypoxyprobe-1 solution (60 mg/kg) 10~40 Pictures were taken under a fluorescence microscope or a light microscope.
Culture of Salmonella ST4 from tissues
Tissues were homogenized in PBS (1:10 w/v ratio) and 10 μl of diluted (10 -1 →10 -5 )
homogenate were dropped on LB agar plates supplemented with 0.5 mM DAP and 25 μg/ml streptomycin. These plates were incubated at 37 ℃ and examined for the presence of colonies.
5'RACE assay for mRNA cleavage products
After first-strand cDNA synthesis, TdT (Terminal transferase) (Life Technologies) and dCTP (Life Technologies) was used to append a poly C + -tail to the cDNA. Anchor primer UAP poly G and PLK1 GSP1 were used for the first around amplification of dC-tailed cDNA.
Nested PCR was performed with 2 μl of the first reaction using the primer UAP and PLK1
GSP2. PCR products were examined by gel electrophoresis, and then cloned into T simple vector (Takara) for sequencing.
Isolation of murine serum
Murine blood was drawn into a serum vial and kept on ice. After congregation for 2 min at 16000×g, the supernatant serum was transferred in fresh tubes and stored -20°C for further use. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of mice were analysed by Reitman and Frankel method. Blood urea nitrogen (BUN) levels were determined by colorimetric method.
Statistics
Data are presented as mean ± standard deviation (SD). Statistical comparisons between two groups were evaluated by Student's t-test and corrected by ANOVA for multiple comparisons. Statistical significance was defined as P values of < 0.05. A log-rand test was used to compare xenograft survival. Prism 5.0 (GraphPad Software) provided the software for statistical analysis.
Results
Development of an Inter-kingdom Dual Expression System
S. typhimurium strain ST3 was engineered with multiple genetic modifications: (1) triple deletions of essential genes: infA for balanced-lethal host-vector system [26] , and auxotrophic genes aroA, asd for further attenuation, (2) To develop a novel inter-kingdom dual expression (IKDE) system with a phage RNAP amplification circuit, a T7 RNAP-based cytoplasmic expression facility was added to the commonly used nuclear system. Transcription of the payloads is enabled by both T7
(cytoplasmic) and CMV (nuclear) promoters to allow a dual expression in the cytoplasm and nucleus respectively. Insertion of a eukaryotic internal ribosome entry site (IRES) prior to the gene of interest was added to augment RNA processing, allowing a cap-independent translation of transcripts produced in the mammalian cytoplasm [27] (Fig. 1A) .
Initially EGFP was used as a foreign gene for a proof-of-concept experiment. 
In vitro screening of potential therapeutic factors by ST3-mediated inter-kingdom gene transfer and RNAi
Using this synthetic inter-kingdom expression platform, intracellular delivery and expression of various cargos could be achieved to assess their therapeutic potential. ST3 harbouring different therapeutic candidates (Table S3) , either protein, DNA or RNA, were used to deliver their cargos into MDA-MB-231 breast cancer cells.
When ST3 carrying a plasmid encoding therapeutic proteins, such as the catalytic fragment of diphtheria toxin (DTA), enters into the mammalian cells. Plasmids, T7 RNAP enzyme and translation-competent mRNA synthesized in the bacterium can pass into the cytoplasm, aided by the LLO generated pores, and then trigger the initial transcription of polymerases by the host ( Fig. 2A) . Driven by the T7 RNAP-autoactivation loop, gene expression substantially increases (Fig. 2B) . Like therapeutic proteins, RNA therapeutic candidates, such as a shRNA against a cancer-related gene, can be delivered and transcribed from a similar plasmid, pIKT-shRNA, encoding a shRNA sequence under the control of T7 promoter. To evaluate the potency of ST3/pIKT-shRNA mediated knockdown of endogenous genes, a shRNA sequence shPlk, which targets a cell cycle-associated protein polo-like kinase 1 (PLK1) [29] was used (Fig. 2C) . Quantitative real-time PCR was used to determine 6.89 ± 0.64 pg of shPlk present in 1 ng bacterial total RNA. By 48 h, ST3/pIKT-shPlk infection exhibited ~80% mRNA inhibition and substantial protein reduction ( Fig. 2D and E) . A series of therapeutic factors were tested in vitro by measuring or monitoring physiological events such as cell death and proliferation (Fig. 2F ). Lead candidates with relatively high potency were then evaluated in animal models. 
ST4/pIKT-DTA therapy reduces tumor burden and malignant ascites while extending survival in the immunocompetent mice with highly aggressive tumors
Tumor-targeting Salmonella ST4 was modified from ST3 ( Fig. S1) , by placing the essential gene asd with a tightly hypoxic regulated control to program the bacterium only survive in anaerobic conditions (Fig. 3A) , such as the hypoxic core of tumors (Fig. 3B) .
Injection of tumor-bearing nude mice with ST4 showed that the bacteria were replication-incompetent in normal organs but could amplify within tumors to as high as 10 By day 2, production of DT-A was observed and its expression level was stably maintained over 2 weeks, after which the mice were sacrificed and primary tumors were harvested (Fig. 4B) . Intracellular presence of bacterial toxins (red) in the cytosol of ST4/pIKT-DTA (green) infected cells, but not in ST4/pIKT-null infected counterparts was revealed by immunofluoresence and DAPI staining (Fig. 4C) and by western blot analysis (Fig. 4D) . Immunohistochemical assay of tumor sections showed that polypeptides were diffused around the bacteria with some molecules transferred to the viable rim (Fig. S4) . Total RNA was reverse transcribed using the target gene specific reverse anchor primer. Data showed that 92.7 ± 1.7% of the transcripts were driven by the T7 RNAP-based cytoplasmic expression, with the remainder driven by the nuclear specific CMV promoter. In situ expression of DT A chain caused a much greater proportion of necrotic areas, significant cell death (1.8 ± 0.18 fold increase in TUNEL-positive cells) and an almost complete absence of proliferating Ki67-positive cells (Fig. 5A ), compared to a control agent.
Moreover, there were significant reductions in pulmonary metastases (P=0.025) in mouse models relative to ST4/pIKT-EGFP treatment (Fig. 5B ), which had a slight inhibitory effect.
Evidence to destruct tumor microenvironment by ST4/pIKT-DTA was also provided by CD105-immunohistochemical staining, indicating the destruction of blood vessels (Fig. S5 ).
Synergistic effects of attenuated Salmonella and the inter-kingdom system allowed the precise expression of DT A chain in tumor microenvironment and eradicated large established tumors (Fig. S6) . Another group consisted of animals carrying tumors of about 200~250 mm 3 , which was found to be optimal for bacterial treatment. A single injection 5×10 6 of ST4/pIKT-DTA resulted in sustained regression over four weeks (Fig. 5C ) and complete survival, whereas mice treated with PBS or ST4/pIKT-EGFP did not survive (Fig. 5D) .
Collectively, these experiments showed that ST4/pIKT-DTA treatment was effective in tumor shrinkage and greatly reduced the risk of death. 
ST4-mediated inter-kingdom RNAi in vivo
We also demonstrated that ST4 packaged with shRNA-encoding plasmids has sustained knockdown effects in nude mice bearing human MDA-MB-231 xenografts. At three weeks after treatments, expression of T7 RNAP in the tumors, as confirmed by quantitative RT-PCR (159.1 ± 67.4 copies/ng RNA), was high and, as intended, led to enhanced shRNA production compared to inoculation with a system lacking this expression ability (ST4/pIKT△T7P-shPlk) (Fig. 6A ). PLK1 transcript levels in tumors treated with ST4/pIKT-shPlk were 75.5 ± 11.5% (P=0.002) and 62.5 ± 18.6% (P=0.015) lower than those in mice injected with PBS (mock control) or ST4/pIKT-shTom (vector control) (Fig. 6B) . The presence of PLK1 5′ RACE-PCR cleavage products confirmed a sustained RNAi-mediated mechanism of action (Fig. 6C, top) .
A clear reduction of PLK1 protein level was shown by western blot analysis (Fig. 6C, bottom) and immunohistochemical assay ( 
Systemic toxicity testing of ST4 harboring inter-kingdom therapeutic system to express cytotoxic proteins or shRNA
To evaluate the health status of mice during the bacterial treatments, the body weight and appearance of mice were monitored every other day. Body weight lost in the first 2~4 days and then recovered to the normal conditions during a 20-day observation period (Fig. 7A ). All the mice have been sacrificed on day 20. Mice had slight enlarged spleens due to slight hematopoiesis (Fig. 7B) . Serum ALT, AST and BUN levels in all treatment groups were in the normal range ( Fig. 7C and D) , which indicated no detectable hepatic stress or kidney injury. To investigate whether the bacterial infection or therapeutic molecules caused any pathological damages in the major organs, the sections of normal tissues have been processed for H&E staining (Fig. 7E) . Gross morphological examination showed that there were no detectable abnormal nodules and apoptotic cell death in the selected organs. These indicated that systemic administration of one injection of ST4/pIKT-DTA or ST4/pIKT-shPlk was well tolerated at the dose level tested (5×10 6 cells/mouse) and the observed antitumor effects were unlikely related to toxic effects. 
Discussion and conclusion
In the past decade, selected bacteria have been exploited as a tiny programmable robot factory and made great strides. Despite of a growing number of bacterial species that apparently exhibit intrinsic tumor-targeting properties, these bacteria generally been found to effective only against relatively small tumors in studies, and no bacterium that is able to inhibit tumor growth completely in fully immunocompetent hosts [30] [31] [32] [33] [34] [35] [36] . Our present study provides a considerable improvement over earlier technologies [13, 34, [37] [38] [39] , in terms of safety, stability, flexibility and efficiency, and the following will highlight some reasons.
Some engineered Salmonella have exerted inherent tumor repression ability in many types of tumor models [33] [34] [35] [36] . These attenuated Salmonella preferentially colonizes various human tumors; however, such bacteria would also colonize spleen and liver, achieving tumor-to-normal tissue accumulation ratios of 1000:1. This biodistribution may cause undesired side effects. To reduce intrinsic bacterial toxicity and achieve precise targeting of tumor microenvironment, a series of genetic manipulations based on the rational designed circuits has been made. After two or three weeks following injection, bacteria were barely detectable in normal organs ( Fig. 3 C and D) . These bacteria selectively grew within the primary tumors and also target to the metastases (Fig. 4A) , which has been shown to be non-pathogenic in both immunocompetent and immunocompromised hosts (Fig. 3 D and E) , suggesting that it is considered safe enough for therapeutic uses. In addition, our system is superior to previous bacterial systems in term of in vivo stability [12, 13] . Firstly, the bacterial factors involved in tumor fitness, intracellular delivery and expression were integrated into the chromosome. Secondly, we used a plasmid encoding a functional translation initiation factor1 from E. coli as selection marker and show that the expression vectors can be maintained in the Salmonella carriers at high copies in vivo (Table S4 ). This system is tightly regulated due to no-cross feeding effects, which is superior to a selection system based on complementation of host auxotrophy [40] .
The Compared to the previously reported bacteria-mediated trans-kingdom RNAi [13] , our technology has three improvements: (1) high tumor-targeting characteristics, (2) in vivo plasmid maintenance, (3) combination of prokaryotic and eukaryotic transcription of shRNA.
In vivo studies suggested that ST4-mediated inter-kingdom RNAi system has achieved a stronger silencing ability and reduce total adverse effects (Fig. S7) .
A series of pathological observations were also made to exclude non-specific toxicity of the above treatments being responsible for the observed effects (Fig. 7) . Taken together, this combined bacterial and eukaryotic plasmid system may also have a place alongside established treatment and vaccination protocols. Table S1 . Bacterial strains and plasmids used in this study. Table S2 . Oligonuclotides used in this study. Table S3 . Potential candidates tested in vitro. Table S4 . Estimate plasmid pcDNA3.1-infA copy numbers by relative qualification. 
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